Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice

被引:91
作者
Steiner, M. A. [1 ,2 ]
Wanisch, K. [1 ]
Monory, K. [2 ]
Marsicano, G. [2 ,3 ]
Borroni, E. [4 ]
Baechli, H. [5 ]
Holsboer, F. [1 ]
Lutz, B. [2 ]
Wotjak, C. T. [1 ]
机构
[1] Max Planck Inst Psychiat, Res Grp Neuronal Plastic, D-80804 Munich, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Physiol Chem, Mainz, Germany
[3] Univ Bordeaux 2, U 862, Ctr Rech, INSERM Francois Magendie, Bordeaux 2, France
[4] F Hoffmann La Roche & Cie AG, Div Pharma, Preclin Res, Basel, Switzerland
[5] Univ Basel Hosp, Dept Neurosurg, CH-4031 Basel, Switzerland
关键词
CB1; forced swim test; endocannabinoids; antidepressants; SR141716; BDNF;
D O I
10.1038/sj.tpj.6500466
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Dysregulation of the endocannabinoid system is known to interfere with emotional processing of stressful events. Here, we studied the role of cannabinoid receptor type 1 (CB1) signaling in stress-coping behaviors using the forced swim test (FST) with repeated exposures. We compared effects of genetic inactivation with pharmacological blockade of CB1 receptors both in male and female mice. In addition, we investigated potential interactions of the endocannabinoid system with monoaminergic and neurotrophin systems of the brain. Naive CB1 receptor-deficient mice (CB1(-/-)) showed increased passive stress-coping behaviors as compared to wild-type littermates (CB1(+/+)) in the FST, independent of sex. These findings were partially reproduced in C57BL/6N animals and fully reproduced in female CB1(+/+) mice by pharmacological blockade of CB1 receptors with the CB1 receptor antagonist SR141716. The specificity of SR141716 was confirmed in female CB1(-/-) mice, where it failed to affect behavioral performance. Sensitivity to the antidepressants desipramine and paroxetine was preserved, but slightly altered in female CB1(-/-) mice. There were no genotype differences between CB1(+/+) and CB1(-/-) mice in monoamine oxidase A and B activities under basal conditions, nor in monoamine content of hippocampal tissue after FST exposure. mRNA expression of vesicular glutamate transporter type 1 was unaffected in CB1(-/-) mice, but mRNA expression of brain-derived neurotrophic factor (BDNF) was reduced in the hippocampus. Our results suggest that impaired CB1 receptor function promotes passive stress-coping behavior, which, at least in part, might relate to alterations in BDNF function.
引用
收藏
页码:196 / 208
页数:13
相关论文
共 50 条
[1]   The endocannabinoid system drives neural progenitor proliferation [J].
Aguado, T ;
Monory, K ;
Palazuelos, J ;
Stella, N ;
Cravatt, B ;
Lutz, B ;
Marsicano, G ;
Kokaia, Z ;
Guzmán, M ;
Galve-Roperh, I .
FASEB JOURNAL, 2005, 19 (09) :1704-+
[2]   Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors [J].
Bilkei-Gorzo, A ;
Racz, I ;
Valverde, O ;
Otto, M ;
Michel, K ;
Sarstre, M ;
Zimmer, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (43) :15670-15675
[3]   Endogenous cannabinoid system as a modulator of food intake [J].
Cota, D ;
Marsicano, G ;
Lutz, B ;
Vicennati, V ;
Stalla, GK ;
Pasquali, R ;
Pagotto, U .
INTERNATIONAL JOURNAL OF OBESITY, 2003, 27 (03) :289-301
[4]   Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function [J].
Cota, Daniela ;
Steiner, Michel-Alexander ;
Marsicano, Giovanni ;
Cervino, Cristina ;
Herman, James P. ;
Gruebler, Yvonne ;
Stalla, Johanna ;
Pasquali, Renato ;
Lutz, Beat ;
Stalla, Guenter K. ;
Pagotto, Uberto .
ENDOCRINOLOGY, 2007, 148 (04) :1574-1581
[5]   The ascent of mouse: Advances in modelling human depression and anxiety [J].
Cryan, JF ;
Holmes, A .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (09) :775-790
[6]   CB1 receptor antagonism increases hippocampal acetylcholine release:: Site and mechanism of action [J].
Degroot, Aldemar ;
Kofalvi, Attila ;
Wade, Mark R. ;
Davis, Richard J. ;
Rodrigues, Ricardo J. ;
Rebola, Nelson ;
Cunha, Rodrigo A. ;
Nomikos, George G. .
MOLECULAR PHARMACOLOGY, 2006, 70 (04) :1236-1245
[7]   Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia [J].
Despres, JP ;
Golay, A ;
Sjostrom, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2121-2134
[8]   Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis [J].
Gobbi, G ;
Bambico, FR ;
Mangieri, R ;
Bortolato, M ;
Campolongo, P ;
Solinas, M ;
Cassano, T ;
Morgese, MG ;
Debonnel, G ;
Duranti, A ;
Tontini, A ;
Tarzia, G ;
Mor, M ;
Trezza, V ;
Goldberg, SR ;
Cuomo, V ;
Piomelli, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (51) :18620-18625
[9]   Antidepressant-induced undesirable weight gain: Prevention with rimonabant without interference with behavioral effectiveness [J].
Gobshtis, Nikolai ;
Ben-Shabat, Shimon ;
Fride, Ester .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 554 (2-3) :155-163
[10]   Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents [J].
Griebel, G ;
Stemmelin, J ;
Scatton, B .
BIOLOGICAL PSYCHIATRY, 2005, 57 (03) :261-267